GleamWall
中文EN

STRO SUTRO BIOPHARMA, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1382101 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-34.4%
TTM net income YoY-74.9%
TTM EPS YoY-2,761.9%
Revenue 3-yr CAGR14.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-175.7%
Net margin-205.2%
FCF margin—
EBITDA margin-168.5%

Returns

ROE-1,810.0%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.32x

Leverage & solvency

Liabilities / assets141.6%
Debt / equity—
Current ratio2.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$102.48M$62.04M
R&D expense$166.42M$252.04M
SG&A expense$41.02M$48.45M
Operating income-$158.37M-$238.45M
Pretax income-$191.18M-$225.10M
Income tax-$93,000$2.36M
Net income-$191.09M-$227.46M
EBITDA-$151.04M-$231.24M
EPS (basic)-22.49-29.40
EPS (diluted)-22.49-29.40
Weighted avg. shares (diluted)8.50M7.74M
Balance sheet
Cash & equivalents$58.13M$190.30M
Short-term investments$83.30M$126.59M
Receivables$3.98M$8.62M
Current assets$150.93M$343.31M
PP&E, net$10.65M$18.19M
Total assets$173.83M$387.21M
Current liabilities$75.13M$131.89M
Total liabilities$306.28M$342.61M
Shareholders' equity-$132.45M$44.60M
Shares outstanding8.58M8.31M
Cash flow statement
Operating cash flow-$177.23M-$191.54M
Investing cash flow$45.01M$218.51M
Financing cash flow$44,000$94.05M
Depreciation & amortization$7.32M$7.22M
Stock-based compensation$14.01M$24.69M

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.